BioSpace News Archive

AbbVie has terminated its license and collaboration deal with Molecular Partners for abicipar pegol, and returned all rights to the Swiss company. Here’s more about it.

Positive topline results from the head-to-head DESTINY-Breast03 phase 3 trial showed that ENHERTU®, the Daiichi Sankyo Company, Limited and AstraZeneca HER2 directed antibody drug conjugate, demonstrated superiority over trastuzumab emtansine.

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, announced financial results for its fiscal 2022 first quarter that ended June 30, 2021.

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 353 owned and/or operated outpatient imaging centers, reported financial results for its second quarter of 2021.

Immunovant, Inc., a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, reported financial results for its fiscal first quarter ended June 30, 2021.

Aravive Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced the Company has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma.

Eagle Pharmaceuticals, Inc. announced financial results for the three and six months ended June 30, 2021.

BioNTech SE, a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, provided an update on its corporate progress and reported financial results for the second quarter and first half-year ended June 30, 2021.

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, reported financial results for the second quarter ended June 30, 2021, and provided an overview of recent operational highlights and a pipeline update.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, reported financial results for the second quarter ended June 30, 2021.